courtesy of Gilead SciencesGilead Sciences Inc. (NASDAQ: GILD) reported second-quarter financial results Tuesday after the markets closed. The biotech giant had $3.15 in earnings per share (EPS) on $8.2 billion in revenue…
Chris Lange ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or…
ThinkstockPharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. (NYSE: MRK)…
Tuesday's top analyst upgrades, downgrades and initiations include Alarm.com, Pandora Media, PayPal, SanDisk, SunEdison, Tesla Motors and Advanced Micro Devices.
24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.
Merrill Lynch recently updated its view on Gilead Sciences, maintaining its Underperform rating for the stock but raising its price objective
Chris Lange The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech stocks was mixed.
The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech stocks, short interest has decreased.
The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks.
S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.
There were some interesting positions of hedge funds in biotech, long and short, from the Goldman Sachs Hedge Fund Trend Monitor.
Back in November of 2010, 24/7 Wall St. first issued a list of stocks to own for the next decade. Even long-term investors need to assess their portfolios from time to time.
It turns out that hedge fund Bridgewater Associates and founder Ray Dalio have made some changes since the end of 2014.
The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks, short interest is down.
Gilead Sciences reported better than expected first-quarter results Thursday after the markets closed.
Chris Lange 